In all-en­com­pass­ing rights deal with Huadong, Di­et­mar Hop­p's Hei­del­berg looks to bring its AD­Cs to most of Asia

Just a few days af­ter Ger­man bil­lion­aire in­vestor Di­et­mar Hopp sunk some of his cash in­to Hei­del­berg Phar­ma, the biotech is cel­e­brat­ing a new li­cens­ing agree­ment that could prove quite lu­cra­tive.

Hei­del­berg signed a deal with Chi­na’s Huadong Med­i­cine, the com­pa­nies an­nounced ear­ly Mon­day morn­ing, giv­ing the Ger­man biotech a po­ten­tial­ly sig­nif­i­cant en­try point in­to most of the Asian mar­ket. Huadong will get ex­clu­sive Asian rights to two of Hei­del­berg’s pro­grams and has the op­tion to li­cense two more pre­clin­i­cal can­di­dates, ex­clud­ing in Japan, In­dia, Pak­istan and Sri Lan­ka.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER